The new ovarian cancer drug Elahere has received an orphan drug designation in Korea.

The Ministry of Food and Drug Safety (MFDS) recently announced the designation through the first orphan drug designation announcement of the new year.

Specifically, the drug is indicated as monotherapy in adult patients with folate receptor-alpha (FRα) positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received one to three prior systemic therapies and have not responded to or are no longer responding to treatment with platinum-based chemotherapy.

AbbVie’s Elahere(mirvetuximab soravtansine) first received accelerated approval in the U.S. in November 20